Adaptive Biotechnologies Corp (ADPT)

$14.10 -0.04 (-0.28%)
Market Cap 2.21B
Revenue (ttm) 178.96M
Net Income (ttm) -159.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.12%
Debt to Equity Ratio 0.00
Volume 1,627,600
Avg Vol 1,882,934
Day's Range N/A - N/A
Shares Out 152.67M
Stochastic %K 6%
Beta 2.09
Analysts Strong Sell
Price Target $19.57

Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 659 0067
Fax: 206 659 0667
Address:
1165 Eastlake Avenue East, Seattle, United States
WallStreetBuyDip
WallStreetBuyDip Nov. 14 at 10:46 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 4:31 PM
Morgan Stanley has updated their rating for Adaptive Biotechnologies ( $ADPT ) to Equal-Weight with a price target of 16.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 9:17 AM
BTIG updates rating for Adaptive Biotechnologies ( $ADPT ) to Buy, target set at 19 → 21.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 9:16 PM
JP Morgan has adjusted their stance on Adaptive Biotechnologies ( $ADPT ), setting the rating to Overweight with a target price of 17 → 20.
0 · Reply
Treasury225
Treasury225 Nov. 6 at 4:11 PM
$ADPT earnings were great and growing. Medicare acceptance of this procedure takes time to work thru the available medical resources. The post/pre market sellers are back in or watching and waiting. Looking forward to new partnerships available as that door is open…
0 · Reply
IN0V8
IN0V8 Nov. 6 at 3:13 PM
$ADPT Buy JP Morgan raises target price to $20 from $17 TD Cowen raises target price to $22 from $18
0 · Reply
Goldenpoint9
Goldenpoint9 Nov. 6 at 11:26 AM
$ADPT
0 · Reply
d_risk
d_risk Nov. 5 at 9:42 PM
$ADPT - Adaptive Biotechnologies Corporation Common Stock - 10Q - Updated Risk Factors ADPT flags risks from the end of its Genentech deal, warning of lost collaboration revenue, hurdles in finding new partners, and threats to innovation and growth. #Biotechnology #PartnershipChallenges #InnovationThreat #RevenueLoss #CollaborationRisk 🟢 Added 🟠 Removed https://d-risk.ai/ADPT/10-Q/2025-11-05
0 · Reply
WAJeff
WAJeff Nov. 5 at 9:33 PM
$ADPT $18.50 52 week high
0 · Reply
ChessGM
ChessGM Nov. 5 at 1:57 PM
$ADPT Earnings focus list for tonight:
0 · Reply
Latest News on ADPT
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Nov 6, 2025, 4:05 PM EST - 8 days ago

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:56 AM EST - 8 days ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 9 days ago

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 4:05 PM EDT - 4 weeks ago

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 3:58 PM EDT - 2 months ago

Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts

Aug 8, 2025, 6:05 AM EDT - 3 months ago

Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts

ASPS

Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 2:13 AM EDT - 3 months ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:05 PM EDT - 3 months ago

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 15, 2025, 4:05 PM EDT - 4 months ago

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Jul 1, 2025, 7:30 AM EDT - 4 months ago

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

May 30, 2025, 7:30 AM EDT - 6 months ago

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 4:05 PM EDT - 6 months ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:46 PM EDT - 7 months ago

Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 7 months ago

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 10, 2025, 4:05 PM EDT - 7 months ago

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Apr 8, 2025, 8:00 AM EDT - 7 months ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 7:47 PM EST - 9 months ago

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:05 PM EST - 9 months ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Jan 22, 2025, 4:05 PM EST - 10 months ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Jan 14, 2025, 7:30 AM EST - 10 months ago

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Jan 7, 2025, 7:30 AM EST - 11 months ago

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 4:05 PM EST - 11 months ago

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Top 3 Health Care Stocks That May Collapse This Quarter

Dec 11, 2024, 6:55 AM EST - 1 year ago

Top 3 Health Care Stocks That May Collapse This Quarter

FNA NAMS

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Dec 7, 2024, 6:30 PM EST - 1 year ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Dec 3, 2024, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Adaptive Biotechnologies: Making Some Progress

Nov 26, 2024, 10:53 AM EST - 1 year ago

Adaptive Biotechnologies: Making Some Progress

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 9:57 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Nov 7, 2024, 7:30 AM EST - 1 year ago

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 9, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 4:03 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:25 PM EDT - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 31, 2024, 7:30 AM EDT - 1 year ago

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:59 PM EDT - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Apr 2, 2024, 4:05 PM EDT - 1 year ago

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Feb 22, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript

Feb 14, 2024, 9:51 PM EST - 1 year ago

Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript

ANY

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Jan 29, 2024, 4:05 PM EST - 1 year ago

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 27, 2023, 4:05 PM EST - 2 years ago

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Dec 9, 2023, 8:30 AM EST - 2 years ago

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

Dec 5, 2023, 7:30 AM EST - 2 years ago

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

WallStreetBuyDip
WallStreetBuyDip Nov. 14 at 10:46 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 4:31 PM
Morgan Stanley has updated their rating for Adaptive Biotechnologies ( $ADPT ) to Equal-Weight with a price target of 16.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 9:17 AM
BTIG updates rating for Adaptive Biotechnologies ( $ADPT ) to Buy, target set at 19 → 21.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 9:16 PM
JP Morgan has adjusted their stance on Adaptive Biotechnologies ( $ADPT ), setting the rating to Overweight with a target price of 17 → 20.
0 · Reply
Treasury225
Treasury225 Nov. 6 at 4:11 PM
$ADPT earnings were great and growing. Medicare acceptance of this procedure takes time to work thru the available medical resources. The post/pre market sellers are back in or watching and waiting. Looking forward to new partnerships available as that door is open…
0 · Reply
IN0V8
IN0V8 Nov. 6 at 3:13 PM
$ADPT Buy JP Morgan raises target price to $20 from $17 TD Cowen raises target price to $22 from $18
0 · Reply
Goldenpoint9
Goldenpoint9 Nov. 6 at 11:26 AM
$ADPT
0 · Reply
d_risk
d_risk Nov. 5 at 9:42 PM
$ADPT - Adaptive Biotechnologies Corporation Common Stock - 10Q - Updated Risk Factors ADPT flags risks from the end of its Genentech deal, warning of lost collaboration revenue, hurdles in finding new partners, and threats to innovation and growth. #Biotechnology #PartnershipChallenges #InnovationThreat #RevenueLoss #CollaborationRisk 🟢 Added 🟠 Removed https://d-risk.ai/ADPT/10-Q/2025-11-05
0 · Reply
WAJeff
WAJeff Nov. 5 at 9:33 PM
$ADPT $18.50 52 week high
0 · Reply
ChessGM
ChessGM Nov. 5 at 1:57 PM
$ADPT Earnings focus list for tonight:
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 1 at 3:47 AM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Treasury225
Treasury225 Oct. 23 at 10:49 PM
$ADPT what the heck is happening after hours?
2 · Reply
XaviersLessons
XaviersLessons Oct. 23 at 7:25 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $ADPT $BTAI $DUO $CODX Watchlist..
0 · Reply
Treasury225
Treasury225 Oct. 22 at 2:11 PM
$ADPT would love to know the story behind the 565,000 shares that traded at 16:27 yesterday that seemed to have a carry over to this mess of an opening today. Makes me question the motives behind this mornings price target update…..
1 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 12:10 PM
BTIG has updated their rating for Adaptive Biotechnologies ( $ADPT ) to Buy with a price target of 19.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 21 at 8:02 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
WAJeff
WAJeff Oct. 15 at 8:09 PM
$ADPT $17.14 52 week high
0 · Reply
WAJeff
WAJeff Oct. 15 at 5:44 PM
More $ADPT sold at $16.50, $16.79 52 week high. This is up 175.4% ytd
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 1:57 PM
Piper Sandler updates rating for Adaptive Biotechnologies ( $ADPT ) to Overweight, target set at 15 → 20.
0 · Reply
DARKP00L
DARKP00L Oct. 13 at 1:20 PM
$ADPT 09:19 on Oct. 13 2025 JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $17 #tradeideas
0 · Reply
DreamCreator
DreamCreator Oct. 9 at 11:03 PM
Keep a close watch on CMCT! $TROX $OCGN $SKYE $ADPT -
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 9 at 7:43 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply